Editorial: HPV-Associated Cancers, Socio-Economic Disparity, and Vaccination by Ghazi Alsbeih
EDITORIAL
published: 13 October 2015
doi: 10.3389/fonc.2015.00223
Edited and reviewed by:
Farhad Islami,
American Cancer Society, USA
*Correspondence:
Ghazi Alsbeih
galsbeih@kfshrc.edu.sa
Specialty section:
This article was submitted to Cancer
Epidemiology and Prevention,
a section of the
journal Frontiers in Oncology
Received: 17 September 2015
Accepted: 30 September 2015
Published: 13 October 2015
Citation:
Alsbeih G (2015) Editorial:
HPV-associated cancers,
socio-economic disparity, and
vaccination.
Front. Oncol. 5:223.
doi: 10.3389/fonc.2015.00223
Editorial: HPV-associated cancers,
socio-economic disparity, and
vaccination
Ghazi Alsbeih*
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Keywords: human papillomavirus, HPV prevalence, HPV genotype, cervical cancer, penile cancer, HIV–HPV
coinfections, cervical cancer screening, social inequalities
I am privileged to guest edit this Frontiers Research Topic addressing HPV infection and cancer
disparities with the expert assistance of Dr. Silvia De Sanjose and Dr. Ala-Eddin Al Moustafa. We
are, hereby, thankful to authors of manuscripts who had responded and enriched the topic with
their valuable contributions. The findings of these manuscripts are interesting and contribute to our
understanding of the complexity of HPV infection, socio-economic inequalities, and related cancers
in a number of unprivileged populations.
Giorgi Rossi and colleagues present an algorithm to model the impact on inequalities of intro-
ducing HPV-based screening of cervical cancer (1). They found that knowledge about HPV and
cervical cancer was lower in women with low socio-economic status and in disadvantaged groups.
The authors conclude that the introduction of HPV test may increase population coverage of the
screening programs, but non-compliance to protocols and interaction with opportunistic screening
can increase the existing inequalities.
Two papers explore HPV infection and cervical cancer screening in migrant populations.
Rodriguez-Sales and colleagues examine the coverage of cervical cancer screening and prevalence
of cytological abnormalities in Catalonia by immigration status (2). They found that cytology
coverage was higher among immigrants who also had a higher prevalence of abnormal Pap smears
compared to the Spanish-born women. The authors recommend to prioritize cervical cancer
screening activities on a regular base in new comers. Tornesello and colleagues assess the prevalence
and HPV genotypes among 499 immigrant women living in Southern Italy (3). They found high
burden of HPV infection, lower participation in screening programs, and high incidence of cervical
cancer in migrant women compared to native Italian. The authors preconize the implementation of
preventive strategies to increase screening, vaccine coverage, and monitoring of uncommon HPV
genotypes potentially spreading in settled population.
Wood and colleagues report on the Canadian first nations (FN) women who endure a dispro-
portionate burden of ill health in contrast to the mainstream population (4). The authors discuss
a participatory action research project, named Anishinaabek Cervical Cancer Screening Study
(ACCSS), investigating the factors underlying the cervical cancer burden in FN women. ACCSS
integrates community engagement, education, and culturally appropriate screening strategies to
reduce the burden of cervical disease in FN communities.
Two manuscripts deal with HPV-related cancers in Middle-Eastern countries Saudi Arabia
and Syria, both lacking national screening and vaccination programs for cervical cancers (5, 6).
The papers presented interesting preliminary findings because there are limited studies about the
prevalence of HPV in the developing countries of the Middle East. Although cervical cancer is
uncommon in Saudi Arabia, the study indicates that HPV prevalence and genotypes’ distribution
show similar pattern as in the world. Both studies emphasize the importance of vaccination against
HPV infection. Nevertheless, a proper cost-effectiveness analysis is required to justify to health
authorities the implementation of a costly vaccine. The authors call for more studies to ascertain
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the real prevalence of HPV at the population level at large, its
association with various types of cancers, and also the impact of
local tradition, emerging behavioral trends to travel for tourism or
immigrations that could affect HPV transmission.
Hernandez and colleagues assessed the HPV prevalence in
79 invasive penile cancer patients diagnosed in 1998–2005 within
7 U.S. cancer registries (7). HPVDNAwas present in 63% of cases
with 17 viral genotypes detected. This is higher than the estimated
40–50% of penile cancers worldwide. Penile cases diagnosed in
more recent years are more likely to be HPV-positive. The authors
concluded that the relatively high prevalence ofHPV in their study
population provides evidence for a more prominent and, possibly,
increasing role of HPV infection in penile carcinogenesis.
Another interesting manuscript by Vogt and colleagues deals
with the concordance of oral and genital HPV infection in
South Africa (8). They state that oral HPV prevalence is similar
in men and women and is slightly higher in human immun-
odeficiency virus (HIV)-infected (13/34) subjects. Genital HPV
prevalence is significantly higher than oral HPV. Oral–oral HPV
concordance between couples is low, but oral–genital and geni-
tal–genital HPV concordance is higher, including concordance of
male oral HPV infection with their partners’ vaginal HPV infec-
tion. The authors conclude that the data is consistent with possible
transmission of vaginal HPV infection to the oral cavity of sexual
partners.
Two manuscripts deal with HPV in women infected with
the HIV (9, 10). McKenzie and colleagues report data on the
HPV genotypes prevalent in 23 histological samples of HIV-
infected women with cervical intraepithelial neoplasia in Miami,
FL, USA (9). The results suggest that cervical dysplasia specimens
of HIV-infected women are more likely (55%) to contain non-16
and -18 high-risk HPV types. The authors conclude that vaccine
development should be more rigorously explored to ensure that
this highly vulnerable population receives appropriate primary
prevention. McDonald and colleagues report data on 1,371 HIV-
positive women and 8,050HIV-negative women fromCape Town,
South Africa (10). In this study, HPV prevalence was higher in
HIV-positive (52.4%) compared to HIV-negative women (20.8%).
The authors conclude that screening strategies incorporatingHPV
genotyping and vaccination should be effective in preventing
cervical cancer in both HIV-positive and -negative women living
in sub-Saharan Africa.
This compilation of manuscripts addresses important health
disparities with regard to HPV infection and related cancers.
HPV infection and cervical cancer is of international interest,
as almost 85% of 530,000 cases diagnosed in 2012 worldwide
occurred in low- and middle-income countries. The social and
economic impact of HPV infection is substantial, as cervical
cancer disproportionately affects more young women. Although
health authorities in many countries do not currently address
these issues, it is important to emphasize thatHPV-related cancers
can be diagnosed early with screening and are largely preventable
with vaccination.
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